Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Sutro Biopharma, Inc. STRO

Healthcare  —  Biotechnology
15.98 0.27 1.72% as of 25 Sep
Market cap
$260.5M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Sutro Biopharma, Inc. (STRO) Business Profile

Updated before January 2025

Company Overview

Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Sutro specializes in the discovery, development, and manufacturing of next-generation oncology therapeutics. The company leverages its proprietary cell-free protein synthesis platform, XpressCF®, to develop antibody-drug conjugates (ADCs), bispecific antibodies, and other protein therapeutics. Sutro’s innovative approach enables the rapid and precise design of complex biologics, positioning it as a leader in the field of targeted cancer therapies.

The company is led by a team of seasoned executives with extensive experience in biotechnology and pharmaceutical development. William J. Newell serves as the Chief Executive Officer, bringing decades of leadership experience in the life sciences industry. Other key members of the leadership team include Trevor Hallam, Ph.D., Chief Scientific Officer, and Arturo Molina, M.D., Chief Medical Officer, who collectively drive Sutro’s scientific and clinical strategies.

Core Business Segments

Sutro Biopharma focuses on the development of oncology therapeutics, with its core business segments centered around the following product categories:

Antibody-Drug Conjugates (ADCs)

Sutro’s ADCs are designed to deliver potent cytotoxic agents directly to cancer cells while minimizing off-target effects. The company’s lead ADC candidate, STRO-002, targets folate receptor alpha (FolRα) and is being developed for the treatment of ovarian and endometrial cancers. Another key ADC, STRO-001, targets CD74 and is in clinical trials for B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma.

Bispecific Antibodies

Sutro is also advancing a pipeline of bispecific antibodies that engage the immune system to target cancer cells. These therapeutics are designed to simultaneously bind to two different antigens, enhancing their specificity and efficacy. Sutro’s bispecific antibody programs are in preclinical and early clinical stages, with a focus on solid tumors and hematologic malignancies.

Collaborations and Partnerships

In addition to its proprietary pipeline, Sutro collaborates with leading pharmaceutical companies to develop novel therapeutics. Notable partnerships include collaborations with Bristol Myers Squibb, Merck KGaA, and EMD Serono. These partnerships leverage Sutro’s XpressCF® platform to accelerate the development of innovative biologics.

Business Model

Sutro Biopharma operates a hybrid business model that combines proprietary drug development with strategic collaborations. The company generates revenue through milestone payments, licensing fees, and royalties from its partnerships. By leveraging its XpressCF® platform, Sutro can rapidly prototype and optimize therapeutic candidates, reducing development timelines and costs.

The company’s vertically integrated approach includes in-house manufacturing capabilities, which provide greater control over the production process and ensure high-quality therapeutics. This integration allows Sutro to efficiently scale its operations as its pipeline progresses through clinical development.

Strategic Direction

Sutro Biopharma is committed to advancing its pipeline of oncology therapeutics while expanding its platform capabilities. Key strategic priorities include:

  • Pipeline Expansion: Sutro aims to advance its lead candidates, STRO-002 and STRO-001, through clinical trials and regulatory approval. The company is also exploring additional indications and combination therapies to maximize the potential of its therapeutics.
  • Platform Innovation: Sutro continues to invest in its XpressCF® platform to enhance its ability to design and produce complex biologics. This includes the development of next-generation ADCs and bispecific antibodies with improved efficacy and safety profiles.
  • Sustainability Goals: Sutro is committed to sustainable manufacturing practices and minimizing its environmental footprint. The company is exploring ways to optimize its production processes and reduce waste.
  • Global Expansion: Sutro plans to expand its presence in international markets through strategic partnerships and collaborations. This includes exploring opportunities in Asia and Europe, where there is significant demand for innovative oncology therapeutics.

Competitive Landscape

Sutro Biopharma operates in a highly competitive biopharmaceutical industry, with several companies developing oncology therapeutics and ADCs. Key competitors include:

  • Seagen Inc.: A leader in ADC development, Seagen has a robust pipeline of oncology therapeutics and a strong commercial presence.
  • ImmunoGen, Inc.: Another prominent player in the ADC space, ImmunoGen focuses on developing targeted cancer therapies.
  • MacroGenics, Inc.: Known for its bispecific antibody programs, MacroGenics competes with Sutro in the immuno-oncology segment.
  • Amgen Inc.: A global biotechnology company with a diverse oncology portfolio, including ADCs and bispecific antibodies.

Despite the competition, Sutro’s proprietary platform and focus on precision biologics provide a competitive edge in the market.

Risk Factors

Sutro Biopharma faces several risks that could impact its business operations and financial performance:

  • Clinical and Regulatory Risks: The success of Sutro’s pipeline depends on the outcomes of clinical trials and regulatory approvals. Delays or failures in these processes could hinder the company’s growth.
  • Market Dependence: Sutro’s revenue is heavily reliant on its lead candidates and partnerships. Any setbacks in these areas could affect its financial stability.
  • Supply Chain Disruptions: As a biopharmaceutical company, Sutro depends on a reliable supply chain for raw materials and manufacturing. Disruptions could impact production timelines and costs.
  • Competition: The biopharmaceutical industry is highly competitive, with numerous companies vying for market share. Sutro must continuously innovate to maintain its competitive position.

Recent Developments

Sutro Biopharma has made significant progress in advancing its pipeline and expanding its partnerships. Recent developments include:

  • Clinical Trial Updates: Sutro announced positive interim data from its Phase 1 clinical trials for STRO-002, demonstrating promising efficacy and safety in ovarian cancer patients.
  • New Collaborations: The company entered into a strategic partnership with a leading pharmaceutical company to develop next-generation ADCs using its XpressCF® platform.
  • Manufacturing Expansion: Sutro completed the construction of a state-of-the-art manufacturing facility to support the production of its clinical and commercial-stage therapeutics.
  • Global Developments: The COVID-19 pandemic highlighted the importance of resilient supply chains and accelerated the adoption of innovative manufacturing technologies, benefiting Sutro’s operations.

Investment Considerations

Investors considering Sutro Biopharma should weigh the following strengths and risks:

Strengths

  • Proprietary XpressCF® platform enables rapid and precise development of complex biologics.
  • Robust pipeline of oncology therapeutics with significant market potential.
  • Strategic partnerships with leading pharmaceutical companies provide additional revenue streams.
  • Vertically integrated operations ensure quality and scalability.

Risks

  • Dependence on clinical trial success and regulatory approvals.
  • High competition in the biopharmaceutical industry.
  • Potential supply chain disruptions and manufacturing challenges.
  • Limited commercial-stage products, with revenue primarily derived from partnerships.

Conclusion

Sutro Biopharma, Inc. is a pioneering biopharmaceutical company with a strong focus on oncology therapeutics. Its proprietary XpressCF® platform and innovative pipeline position it as a leader in the development of next-generation ADCs and bispecific antibodies. While the company faces risks inherent to the biopharmaceutical industry, its strategic direction, robust partnerships, and commitment to innovation provide a solid foundation for future growth. As Sutro advances its pipeline and expands its global presence, it is well-positioned to make a significant impact in the fight against cancer.